INVO

INVO Bioscience

Page Views : 219461

company profile

INVO Bioscience, Inc. (NASDAQ: INVO) is a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. Their flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Their primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC”, provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”). Our commercialization strategy is focused on the opening of dedicated “INVO Centers” offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.

Sector

Healthcare

Industry

Medical Devices

Exchange

Nasdaq

Ticker

INVO

vista's key points

INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics to accelerate adoption of INVOcell and their business worldwide.
INVO now has distribution agreements in place in within 9 countries in Africa, Asia (China, Taiwan), Europe, & Middle East continues to seek further relationships worldwide.
INVO opened INVOcell dedicated clinics or INVO Centers in Atlanta, Birmingham, & Monterrey, Mexico & reportedly the buildout of the Company's new Tampa, Florida clinic – Tampa Fertility Institute, an INVO Center – is near completion and patient services are expected to commence this summer.
INVO expanded our commercialization approach to include the acquisition of established and profitable US IVF clinics and announced the execution of binding agreements to acquire Wisconsin Fertility Institute that was named One of America's Best Fertility Clinics by Newsweek.
Wisconsin Fertility Institute is a fertility center that primarily offers conventional in vitro fertilization ("IVF") procedures and generated approximately $5.5M in revenue and net income of approximately $1.9M for the trailing 12-month period ended September 30, 2022.
INVO's acquisition strategy is highly complementary to their ongoing efforts to build new INVO Centers, increase sales of our INVOcell® device, and expand adoption of the IVC procedure. They expect this strategy to accelerate our corporate development efforts and their path to profitability, as they integrate IVC alongside IVF.
INVO is now a "microfloat" as of July 28, 2023 immediately after a reverse stock split became effective. The company now has ~842,017 shares of common stock issued and outstanding. In addition, a proportionate adjustment was made to the company's authorized shares of common stock such that the Company shall have 6,250,000 shares of authorized common stock after the effective time of the reverse stock split.

Click Here To Learn More

Trade Now

VISTA'S PROGRESS REPORT

INVO Bioscience (NASDAQ: INVO), A Company Seeking To Address A Massively Underserved Fertility Market

As Vista readers know, we are huge fans of hidden gems and/or little known companies that have unique offerings and which are believed to have promise of addressing huge unmet needs of a market, especially in the healthcare sector. We’re looking today toward one medtech company, INVO Bioscience (NASDAQ: INVO), that tells a compelling story in the future of fertility. Each day, more and more people are waking up to see the significant problem that is infertility. According to the World Health Organization, infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. Availability, access, and quality of interventions to address infertility remain a challenge in most countries. Tesla (TSLA) CEO, Elon Musk, has also been recently commenting on the falling birth rates with quotes like, “Population collapse is the biggest danger civilization faces by far.” He added, “Mark my words, they are sadly true.” The pressure is building for the sustainability of mankind, and many of today’s thought leaders are starting to vocalize the impending doom and the need to adapt news ways. According to an article via the World Economic Forum, “If they aren’t already, dozens of countries’ populations will be going into decline in this century, according to a study published in the Lancet. 23 countries are expected to feel this effect intensify, with their populations dropping to half of what they are now by the year 2100.”

INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics to accelerate adoption of INVOcell and their business worldwide.
INVO now has distribution agreements in place in within 9 countries in Africa, Asia (China, Taiwan), Europe, & Middle East continues to seek further relationships worldwide.
INVO opened INVOcell dedicated clinics or INVO Centers in Atlanta, Birmingham, & Monterrey, Mexico & reportedly the buildout of the Company's new Tampa, Florida clinic – Tampa Fertility Institute, an INVO Center – is near completion and patient services are expected to commence this summer.
INVO expanded our commercialization approach to include the acquisition of established and profitable US IVF clinics and announced the execution of binding agreements to acquire Wisconsin Fertility Institute that was named One of America's Best Fertility Clinics by Newsweek.
Wisconsin Fertility Institute is a fertility center that primarily offers conventional in vitro fertilization ("IVF") procedures and generated approximately $5.5M in revenue and net income of approximately $1.9M for the trailing 12-month period ended September 30, 2022.
INVO's acquisition strategy is highly complementary to their ongoing efforts to build new INVO Centers, increase sales of our INVOcell® device, and expand adoption of the IVC procedure. They expect this strategy to accelerate our corporate development efforts and their path to profitability, as they integrate IVC alongside IVF.
INVO is now a "microfloat" as of July 28, 2023 immediately after a reverse stock split became effective. The company now has ~842,017 shares of common stock issued and outstanding. In addition, a proportionate adjustment was made to the company's authorized shares of common stock such that the Company shall have 6,250,000 shares of authorized common stock after the effective time of the reverse stock split.

Click Here To Learn More

Sector

Healthcare

Industry

Medical Devices

Exchange

Nasdaq

Ticker

INVO